Skip to main content
. 2020 Jan 28;21(3):829. doi: 10.3390/ijms21030829

Figure 1.

Figure 1

Immunoepigenetic therapeutic strategies for urological malignancies. Since there is evidence that the tumor immune response is epigenetically regulated, there is rationale for combining epigenetic modifiers with immune therapies, in order to achieve better clinical outcome. Abbreviations: APC—antigen presenting cell; BET—bromodomain extra-terminal; CTLA-4—cytotoxic T-lymphocyte associated antigen; DC—dendritic cell; HDAC—histone deacetylase; PD-(L)1—programmed death (ligand) 1.